CSL trades at a discount despite owning a dominant, hard-to-replicate global plasma-derived therapies infrastructure. Transformation Program targets $500–$550M in annual pre-tax cost reductions by ...
Amid uncertainty for its vaccine division, CSL is growing the footprint of its bread-and-butter plasma therapies business by pledging a capital investment of about $1.5 billion for U.S.-based ...
With a new CEO, a new subsidiary, a newly approved gene therapy and three R&D centers under construction on three different continents, change is coming fast for CSL Limited. Established more than a ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company is also closing two ...
We transfer coverage of CSL, a global leader in plasma therapies, influenza vaccinations, and iron and kidney products. Shares have plummeted over 60% in the last two years on several earnings ...
Illinois Gov. JB Pritzker on Monday announced a $1.5 billion investment from biotherapeutics company CSL for a new plasma therapy manufacturing plant in Kanakee. CSL will expand its current footprint ...
CSL Behring's new R&D facility will be 40,000 square meters, including 7,000 square meters of lab space. (CSL Behring) CSL Behring has made a name for itself manufacturing biologics and plasma, but ...
SYDNEY, Feb 11 (Reuters) - CSL Ltd (CSL.AX), opens new tab on Wednesday reported an 81% drop in first‑half profit, knocked by weaker blood plasma product and vaccine sales and one-off charges, a day ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results